Earnings Scheduled For October 27, 2021
Companies Reporting Before The Bell
• McDonald's (NYSE:MCD) is expected to report quarterly earnings at $2.46 per share on revenue of $6.03 billion.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
Boston Scientific’s Eluvia Drug-Eluting Vascular Stent Tops Bare Metal Stents
Boston Scientific Corporation (NYSE:BSX) has announced data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) at the Vascular InterVentional Advances…
Boston Scientific Says Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
Today, Boston Scientific Corporation (NYSE:BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular
Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal
Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Baylis Medical Company Inc for an upfront payment of $1.75 billion. The acquisition will…
Boston Scientific Highlights Trial Data For EkoSonic System For Pulmonary Embolism
Boston Scientific Corporation (NYSE:BSX) announced results for the EkoSonic Endovascular System at the Vascular InterVentional Advances (VIVA) meeting. Related: Boston Scientific Acquires…
Boston Scientific Highlights Late-Breaking Clinical Trial Data For Its EkoSonic Endovascular System Presented At Vascular InterVentional Advances
Today, Boston Scientific (NYSE:BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA)
Boston Scientific Reports Results For Ranger Drug-Coated Balloon During Late-Breaking Presentation At Vascular InterVentional Advances Meeting
Today, Boston Scientific (NYSE:BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in
UPDATE: Boston Scientific Sees FY21 Durable Organic Sales Growth 19-20%, Adj. EPS $1.58-$1.62 vs $1.61 Estimate
https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/documents/events/BSX-Investor-Day-2021-22Sep-final-final.pdf
UPDATE: Boston Scientific Investor Day Presentation Shows 6-8% Organic Sales Growth For FY22-FY24, Adj. EPS Growth In Double Digit Range
https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/documents/events/BSX-Investor-Day-2021-22Sep-final-final.pdf